Chris Webber1, Michael Patton2, Scott Patterson3, Beate Schmoele-Thoma4, Susanne M Huijts5, Marc J M Bonten6. 1. Pfizer Vaccines Clinical Research and Development, Pearl River, NY, USA. Electronic address: Chris.Webber@pfizer.com. 2. Pfizer Vaccines Clinical Research and Development, Maidenhead, UK. Electronic address: Michael.Patton@pfizer.com. 3. Pfizer Vaccines Clinical Research and Development, Collegeville, PA, USA. Electronic address: Scott.Patterson@pfizer.com. 4. Pfizer Vaccines Clinical Research and Development, Berlin, Germany. Electronic address: Beate.Schmoele-Thoma@pfizer.com. 5. Julius Center for Health Sciences and Primary Care, UMC Utrecht, Netherlands; Department of Respiratory Medicine, UMC Utrecht, Netherlands. Electronic address: S.M.Huijts@umcutrecht.nl. 6. Julius Center for Health Sciences and Primary Care, UMC Utrecht, Netherlands. Electronic address: M.J.M.Bonten@umcutrecht.nl.
Abstract
BACKGROUND: The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) assessed vaccine-type community-acquired pneumonia (VT-CAP) and vaccine-type invasive pneumococcal disease (VT-IPD) prevention with 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾65years. We report vaccine efficacy (VE) of PCV13 for the remaining 23 exploratory endpoints and serotype distributions for pneumococcal CAP and IPD. METHODS: This was a parallel-group, randomised, placebo-controlled, double-blind trial comparing single-dose PCV13 with placebo. Exploratory CAP endpoints included first episode of confirmed non-VT (NVT) pneumococcal CAP; all confirmed episodes of NVT pneumococcal CAP, pneumococcal CAP, nonbacteraemic/noninvasive (NB/NI) VT pneumococcal CAP, and NB/NI pneumococcal CAP; and first and all episodes of culture-confirmed VT pneumococcal CAP, culture-confirmed pneumococcal CAP, culture-confirmed NVT pneumococcal CAP, probable VT pneumococcal CAP, probable NVT pneumococcal CAP, and probable and possible pneumococcal CAP. Exploratory IPD endpoints included all episodes of VT-IPD and IPD, and first and all episodes of NVT-IPD. The per-protocol and modified intent-to-treat (mITT) populations were evaluated. RESULTS: In total, 84,496 participants were enrolled. Eight of 23 exploratory CAP and IPD endpoints were statistically significant in both populations. In the per-protocol population, these included VE of 29% for all episodes of confirmed pneumococcal CAP, 43% for all NB/NI episodes of VT pneumococcal CAP, 52% for all episodes of culture-confirmed pneumococcal CAP, and 53% for all episodes of IPD. Comparable VE estimates were observed in the mITT population. The most common VT serotypes were 1 (10 first episodes of confirmed pneumococcal CAP; 2 first episodes of IPD) and 7F (22; 7) among PCV13 and placebo recipients, respectively. CONCLUSIONS: The results of this analysis yielded statistically significant PCV13 VE for all episodes of confirmed pneumococcal CAP (including NB/NI and culture-confirmed episodes) and for all episodes of IPD in adults aged ⩾65years. These findings are consistent with the primary efficacy analysis. ClinicalTrials.gov identifier: NCT00744263.
RCT Entities:
BACKGROUND: The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) assessed vaccine-type community-acquired pneumonia (VT-CAP) and vaccine-type invasive pneumococcal disease (VT-IPD) prevention with 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾65years. We report vaccine efficacy (VE) of PCV13 for the remaining 23 exploratory endpoints and serotype distributions for pneumococcal CAP and IPD. METHODS: This was a parallel-group, randomised, placebo-controlled, double-blind trial comparing single-dose PCV13 with placebo. Exploratory CAP endpoints included first episode of confirmed non-VT (NVT) pneumococcal CAP; all confirmed episodes of NVT pneumococcal CAP, pneumococcal CAP, nonbacteraemic/noninvasive (NB/NI) VT pneumococcal CAP, and NB/NI pneumococcal CAP; and first and all episodes of culture-confirmed VT pneumococcal CAP, culture-confirmed pneumococcal CAP, culture-confirmed NVT pneumococcal CAP, probable VT pneumococcal CAP, probable NVT pneumococcal CAP, and probable and possible pneumococcal CAP. Exploratory IPD endpoints included all episodes of VT-IPD and IPD, and first and all episodes of NVT-IPD. The per-protocol and modified intent-to-treat (mITT) populations were evaluated. RESULTS: In total, 84,496 participants were enrolled. Eight of 23 exploratory CAP and IPD endpoints were statistically significant in both populations. In the per-protocol population, these included VE of 29% for all episodes of confirmed pneumococcal CAP, 43% for all NB/NI episodes of VT pneumococcal CAP, 52% for all episodes of culture-confirmed pneumococcal CAP, and 53% for all episodes of IPD. Comparable VE estimates were observed in the mITT population. The most common VT serotypes were 1 (10 first episodes of confirmed pneumococcal CAP; 2 first episodes of IPD) and 7F (22; 7) among PCV13 and placebo recipients, respectively. CONCLUSIONS: The results of this analysis yielded statistically significant PCV13 VE for all episodes of confirmed pneumococcal CAP (including NB/NI and culture-confirmed episodes) and for all episodes of IPD in adults aged ⩾65years. These findings are consistent with the primary efficacy analysis. ClinicalTrials.gov identifier: NCT00744263.
Authors: Paul S Schulz; Sarah E Moore; Daniel Smith; Jessica Javed; Ashley M Wilde Journal: Open Forum Infect Dis Date: 2022-03-16 Impact factor: 3.835
Authors: Shmuel Shoham; Evan M Bloch; Arturo Casadevall; Daniel Hanley; Bryan Lau; Kelly Gebo; Edward Cachay; Seble G Kassaye; James H Paxton; Jonathan Gerber; Adam C Levine; Judith Currier; Bela Patel; Elizabeth S Allen; Shweta Anjan; Lawrence Appel; Sheriza Baksh; Paul W Blair; Anthony Bowen; Patrick Broderick; Christopher A Caputo; Valerie Cluzet; Marie Elena Cordisco; Daniel Cruser; Stephan Ehrhardt; Donald Forthal; Yuriko Fukuta; Amy L Gawad; Thomas Gniadek; Jean Hammel; Moises A Huaman; Douglas A Jabs; Anne Jedlicka; Nicky Karlen; Sabra Klein; Oliver Laeyendecker; Karen Lane; Nichol McBee; Barry Meisenberg; Christian Merlo; Giselle Mosnaim; Han-Sol Park; Andrew Pekosz; Joann Petrini; William Rausch; David M Shade; Janna R Shapiro; J Robinson Singleton; Catherine Sutcliffe; David L Thomas; Anusha Yarava; Martin Zand; Jonathan M Zenilman; Aaron A R Tobian; David Sullivan Journal: medRxiv Date: 2021-12-14
Authors: Rosa Prato; Francesca Fortunato; Maria Giovanna Cappelli; Maria Chironna; Domenico Martinelli Journal: BMJ Open Date: 2018-03-25 Impact factor: 2.692